Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular riskPRNewsWire • 07/25/25
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)GlobeNewsWire • 06/20/25
VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERVBusiness Wire • 06/19/25
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From LillyZacks Investment Research • 06/17/25
VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to ShareholdersBusiness Wire • 06/17/25
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly TakeoverInvestors Business Daily • 06/17/25
Shareholder Alert: The Ademi Firm Investigates Whether Verve Therapeutics, Inc. Is Obtaining a Fair Price for Its Public ShareholdersBusiness Wire • 06/17/25
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies sayReuters • 06/17/25
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular riskPRNewsWire • 06/17/25
Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%.Barrons • 06/17/25
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reportsReuters • 06/16/25
Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving AverageZacks Investment Research • 06/06/25
Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High?Zacks Investment Research • 06/05/25
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 06/02/25